RetroNose®: target nasal drug delivery through oral administration
The RetroNose® concept has been developed* to reduce variability and improve drug deposition in specific nasal zones, consisting of drug administration through the buccal cavity during the nasal expiratory phase.
The concept of nasal drug delivery via the oral route using a pressurized metered dose inhaler (pMDI) in an upper airways model has been demonstrated in vitro, with promising results. All anatomical regions, except for the upper part of the nasal cavity, were successfully targeted, with relatively homogenous deposition. This nasal drug delivery system could be of interest for both local and systemic drug delivery, and for the delivery of vaccines.
* in collaboration with the Research Center for Respiratory Diseases (CEPR) of Inserm and the University of Tours (France)
- pMDI concept technology with an adapted mouthpiece and innovative trigger mechanism
- Nasal drug delivery through buccal aerosol administration
- Spray triggering upon positive pressure in the buccal cavity during nasal expiratory phase
- Better treatment efficacy with lower drug amount* thanks to a fairly homogeneous deposition in the nasal cavities
- Low variability in terms of deposition distribution vs nasal pumps
- Opportunity of treating nose and throat in one-go
- Reduced patient-to-patient variability by avoiding the nasal valve passage
* To be verified with a clinical trial
To watch this video you must consent the use of cookies.
